⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 24, 2024JAAD Case ReportsOpen Access

Zanubrutinib-induced petechial ecchymotic reaction in a previously irradiated area in a patient with chronic lymphocytic leukemia

Serena Vilasi Lydia A. Luu Mary M.B. Noland

View Full Paper

Ask AI

Bookmark

Share

Abstract

The first Bruton's tyrosine kinase (BTK) inhibitor ibrutinib was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of chronic lymphocytic leukemia (CLL). First-generation BTK inhibitors have revolutionized the treatment of lymphoproliferative disorders but carry risk of dermatologic toxicities such as ecchymoses, rash, and skin infection.1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vilasi et al. (2024) studied this question.

synapsesocial.com/papers/68e77c7cb6db6435876f0833 https://doi.org/10.1016/j.jdcr.2024.01.020

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma2024 · 1 citations
2Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated reviewReview · 2026
3Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor2024 · 2 citations
4Challenges associated with the use of Bruton's tyrosine kinase inhibitors: A life‑saving therapy for chronic lymphocytic leukemia (Review)2024 · 3 citations
5Bruton tyrosine kinase inhibitors and cardiovascular adverse eventsreview · 2026